Non-Genital WartsPhase 2/3NCT06691542
Efficacy and Safety of Platelet-rich Plasma, Metformin and Cryotherapy in Treatment of Non-genital Warts
A Phase 2/3 study testing platelet-rich plasma, Metformin and cryotherapy in people with Non-Genital Warts, run by Assiut University.
Trial summary
1. Evaluation of the efficacy and safety of intralesional injection of autologous platelet-rich plasma in treatment of various types of cutaneous non genital warts 2. Evaluation of the efficacy and safety of intralesional injection of metformin in treatment of various types of cutaneous non genital warts 3. Read more about this study
- Who is it for?
- Ages 8 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Non-Genital Warts
- What is being tested?
- platelet-rich plasma, Metformin and cryotherapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- No sites listed yet
- Study dates
- 14 Nov 2024to Apr 2025
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 60 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Patients with cutaneous (extragenital) viral warts (single , new or recurrent, common, plane and/or planter warts.
- Age ranged from 8 to 60 years old.
- No concurrent systemic or topical treatment of warts.
Who cannot join
- Patients with fever or signs of any inflammation or infection
- Pregnancy and lactation.
- Immunosuppression or being under any kind of treatment causing absolute or relative immunosuppression.
- History of any bleeding, clotting disorder or using anticoagulants
- Chronic systemic diseases such as diabetes, chronic renal failure, hepatic insufficiency, and cardiovascular disorders.
- atients using concurrent treatments for warts or one month before .
- Any generalized dermatitis, allergic skin disorders
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
- Evaluation of the efficacy and safety of intralesional injection of autologous platelet-rich plasma in treatment of various types of cutaneous non genital warts
- Evaluation of the efficacy and safety of intralesional injection of metformin in treatment of various types of cutaneous non genital warts
- Comparing the efficacy and safety of intralesional injection of autologous platelet-rich plasma and intralesional injection of metformin with that of cryocautery in treatment of various types of cutaneous non genital warts.
Read the detailed description
Cutaneous warts caused by human papillomavirus (HPV) are benign proliferative lesions that occur at any age in human life.
More than 100 different types of HPVs have been fully characterized . Warts may exist in different forms according to the epithelial surface affected and HPV type responsible for the infection. Common warts (Verruca vulgaris), plantar warts (Verruca plantaris), flat or plane warts (Verruca plana) and genital warts (Condyloma acuminata) are some of the clinical manifestations of HPV infection .
Although lesions can resolve spontaneously within 2 years without treatment, treatment is sought by many who are unwilling to wait for spontaneous clearance, by those who do not experience such resolution and for reasons of preventing infections of other individuals and reducing the risk of malignancy . Additionally, pain, discomfort, recurrent bleeding, functional limitation, and esthetic disfigurements due to cutaneous warts are common indications for seeking treatment.
Several therapeutic modalities have been used to treat HPV infections. The choice of treatment should take into account factors such as age, location, number and size of the lesions, clinical subtype and the patient's immunological status.
Available treatments are aimed at either breakdown or removal of visible warts or induction of cytotoxicity against infected cells .
They include destructive agents (keratolytic, cryotherapy, curettage and cautery, laser, photodynamic therapy), antimitotic agents (podophyllin, bleomycin, retinoids), immune stimulants (topical sensitizers, cimetidine), and topical virucidal agents [formaldehyde (formalin), glutaraldehyde (Glutaral) .
Unfortunately, no single treatment is satisfactory for all patients. Many treatments are time consuming, painful and can leave scars or hypopigmentation; moreover, recurrence rates after any treatment range from 6% to 100% . So, the development of new effective and safe treatments seems to be an urgent need.
Cryocautery represents a first line of therapy for cutaneous warts. It uses liquid nitrogen to freeze tissues and destroy warts.
Liquid nitrogen cryotherapy involves freezing a wart with liquid nitrogen for 10 to 20 seconds every two to three weeks. Precisely how cryotherapy destroys warts is not well understood, but the prevailing theory is that freezing causes local irritation, leading the host to mount an immune reaction against the virus.
However, side effects for cryocautery are common, they include pain, depigmentation, delayed healing, ulceration, scar formation and recurrence
Platelet- rich plasma (PRP) is a small volume of plasma rich in platelets. It has become a hopeful therapy in the last decade to treat several cutaneous diseases due to its increased concentrations of growth factors. As it is of autologous origin, it reduces the possibility of adverse effects and transfusion transmitted infections.
PRP has been utilized in the treatment of numerous cutaneous diseases such as alopecia, skin ulcers, and acne vulgaris. Its utility has been extended to other cutaneous diseases as melasma, hyperpigmentation, and burns, in addition to its usefulness in tissue repair and regeneration.
To the best of our knowledge the efficacy of PRP in the treatment of plane warts was assessed in a single uncontrolled clinical trial which revealed that intralesional injection of PRP was effective and well-tolerated immunotherapy for treating of multiple recalcitrant plane warts.
Moreover, complete remission of multiple resistant plantar warts after treatment by combined intralesional autologous PRP injections and local application of salicylic acid 30% was observed in only one case report.
Mechanisms suggested for such promising response of warts to intralesional injection of PRP included induction of expression of numerous pro-inflammatory cytokines as interleukin-6, interleukin-8, tumor necrosis factor-alpha, and C-C motif chemokine ligand 5 which then activate several immune cells leading to increased inflammation.
Also, platelets expressed CD40L, on its activation; it modulates its interaction with CD40 presenting on macrophages, B-cells, monocytes, endothelial cells, dendritic cells, and mediates their activities.
Platelets may modulate the innate immunity and provide antimicrobial activities either by synthesis of antimicrobial peptides or by modulating the immune activities of other immune cells as neutrophils and monocytes.
These interesting findings open the way for future studies to evaluate the usefulness of PRP in treating different clinical types of warts.
Metformin, a widely used drug to treat type 2 diabetes mellitus and metabolic syndrome, has been used systemically in different dermatological diseases such as hormonal acne, hidradenitis suppurativa (HS) and acanthosis nigricans in which it may act through improving hyperinsulinemia . Additionally, it was found effective when used topically in treatment of melasma with an equivalent effect to triple combination cream , and acne vulgaris .
Metformin has immunomodulatory activity that reduces the production of proinflammatory cytokines, it also inhibits the cytokine production of pathogenic Th1 and Th17 cells .
Furthermore, many studies, both in vitro and in vivo with small animal models, have highlighted the antiviral properties of metformin.
Additionally, Metformin has shown antitumorigenic potential in HPV-positive cancer cells. Such properties suggests that metformin might be effective therapeutic option for viral warts. However, to the best of our knowledge, no studies have been conducted to explore that hypothesis.
- Conditions
- Non-Genital Warts
- Being tested
- platelet-rich plasma, Metformin, cryotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
platelet-rich plasmaDrug
platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
MetforminDrug
platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
cryotherapyOther
platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
| Study group | Role | What they receive |
|---|---|---|
| Intralesional injection of Metformin | Experimental | Group 1: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of metformin using insulin syringe every 2-weeks until complete clearance or for a maximum of 6 sessions. Receives: Drug: Metformin |
| Intralesional injection of platelet- rich plasma | Experimental | Group 2: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of platelet- rich plasma into the warts by an insulin syringe every 2 weeks until complete clearance or for a maximum of 6 sessions Receives: Drug: platelet-rich plasma |
| Cryotherapy | Experimental | Group 3: will include 36 patients with multiple common, plantar and/or plane warts. They will receive cryotherapy sessions every two weeks until complete clearance or for a maximum of 6 sessions. Receives: Other: cryotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings
Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings
Measured: 3 months
Secondary outcomes (3)
•Change in size in millemeter
Change in size in millemeter
Measured: 3 months
•Decrease in numbers of the warts
Decrease in numbers of the warts
Measured: 3 months
•Recurrence rates at 3 months for wart(s) with complete resolution.
Recurrence rates at 3 months for wart(s) with complete resolution.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2024
- Study start14 Nov 2024 (estimated)
- Primary completionMar 2025 (estimated)
- Study completionApr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Non-Genital WartsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya Gamal Abd El-Wahab Mahmoud, Assiut University
- Investigators
- Eman Mohamed Kamal Elsayed Youssef, prof, Principal investigator, Professor of Dermatology and Venereology Faculty of Medicine, Assiut UniversityAlaa Mohamed Mahmoud Hamdy Ghazally, Lecturer, Principal investigator, Lecturer of Dermatology and Venereology Faculty of Medicine, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06691542
- Sponsor's protocol ID
- PRP, Metformin in warts
- Status last verified
- Nov 2024
- First submitted
- 9 Feb 2024
- Last updated
- 15 Nov 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Zhu P, Qi RQ, Yang Y, Huo W, Zhang Y, He L, Wang G, Xu J, Zhang F, Yang R, Tu P, Ma L, Liu Q, Li Y, Gu H, Cheng B, Chen X, Chen A, Xiao S, Jin H, Zhang J, Li S, Yao Z, Pan W, Yang H, Shen Z, Cheng H, Song P, Fu L, Chen H, Geng S, Zeng K, Wang J, Tao J, Chen Y, Wang X, Gao XH. Clinical guideline for the diagnosis and treatment of cutaneous warts (2022). J Evid Based Med. 2022 Sep;15(3):284-301. doi: 10.1111/jebm.12494. Epub 2022 Sep 18.
PubMed 36117295Araujo MG, Magalhaes GM, Garcia LC, Vieira EC, Carvalho-Leite MLR, Guedes ACM. Update on human papillomavirus - Part II: complementary diagnosis, treatment and prophylaxis. An Bras Dermatol. 2021 Mar-Apr;96(2):125-138. doi: 10.1016/j.abd.2020.11.005. Epub 2021 Feb 16.
PubMed 33637397Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct;171(4):696-712. doi: 10.1111/bjd.13310. Epub 2014 Oct 1. No abstract available.
PubMed 25273231Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005 Aug 15;72(4):647-52.
PubMed 16127954Focht DR 3rd, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med. 2002 Oct;156(10):971-4. doi: 10.1001/archpedi.156.10.971.
PubMed 12361440Abu El-Hamd M, Aboeldahab S. Possible clinical efficacy and tolerability of platelet-rich plasma in the treatment of patients with recalcitrant plane warts: The first clinical study. J Cosmet Dermatol. 2021 Nov;20(11):3623-3629. doi: 10.1111/jocd.14008. Epub 2021 Mar 1.
PubMed 33599062Abu El-Hamd M, Aboeldahab S. A case of resistant multiple plantar warts cured with combined autologous platelet-rich plasma injection and topical salicylic acid 30. J Cosmet Dermatol. 2022 Jun;21(6):2417-2419. doi: 10.1111/jocd.14468. Epub 2021 Sep 24.
PubMed 34559938McDonald B, Dunbar M. Platelets and Intravascular Immunity: Guardians of the Vascular Space During Bloodstream Infections and Sepsis. Front Immunol. 2019 Oct 11;10:2400. doi: 10.3389/fimmu.2019.02400. eCollection 2019.
PubMed 31681291Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 Feb 5;391(6667):591-4. doi: 10.1038/35393.
PubMed 9468137Flad HD, Brandt E. Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci. 2010 Jul;67(14):2363-86. doi: 10.1007/s00018-010-0306-x. Epub 2010 Mar 7.
PubMed 20213276Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front Immunol. 2020 Aug 18;11:2056. doi: 10.3389/fimmu.2020.02056. eCollection 2020.
PubMed 32973814Benedetti F, Sorrenti V, Buriani A, Fortinguerra S, Scapagnini G, Zella D. Resveratrol, Rapamycin and Metformin as Modulators of Antiviral Pathways. Viruses. 2020 Dec 17;12(12):1458. doi: 10.3390/v12121458.
PubMed 33348714Hoppe-Seyler K, Herrmann AL, Daschle A, Kuhn BJ, Strobel TD, Lohrey C, Bulkescher J, Krijgsveld J, Hoppe-Seyler F. Effects of Metformin on the virus/host cell crosstalk in human papillomavirus-positive cancer cells. Int J Cancer. 2021 Sep 1;149(5):1137-1149. doi: 10.1002/ijc.33594. Epub 2021 May 6.
PubMed 33844847Abou-Taleb DAE, Abou-Taleb HA, El-Badawy O, Ahmed AO, Thabiet Hassan AE, Awad SM. Intralesional vitamin D3 versus intralesional purified protein derivative in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther. 2019 Sep;32(5):e13034. doi: 10.1111/dth.13034. Epub 2019 Aug 7.
PubMed 31355514Abd El-Magiud EM, Abd El-Samea GM, Gaber HD. Intralesional injection of measles, mumps, and rubella vaccine versus cryotherapy in treatment of warts: A randomized controlled trial. Dermatol Ther. 2020 Mar;33(2):e13257. doi: 10.1111/dth.13257. Epub 2020 Feb 16.
PubMed 32031726
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Platelet-rich Plasma, Metformin and Cryotherapy in Treatment of Non-genital Warts
- ClinicalTrials.gov ID
- NCT06691542
- Acronym / sponsor ID
- PRP, Metformin in warts
- Conditions
- Non-Genital Warts
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 14 Nov 2024 (estimated)
- Primary completion
- Mar 2025 (estimated)
- Study completion
- Apr 2025 (estimated)
- First posted
- 15 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- Evaluation of the efficacy and safety of intralesional injection of autologous platelet-rich plasma in treatment of various types of cutaneous non genital warts
- Evaluation of the efficacy and safety of intralesional injection of metformin in treatment of various types of cutaneous non genital warts
- Comparing the efficacy and safety of intralesional injection of autologous platelet-rich plasma and intralesional injection of metformin with that of cryocautery in treatment of various types of cutaneous non genital warts.
Detailed description
Cutaneous warts caused by human papillomavirus (HPV) are benign proliferative lesions that occur at any age in human life.
More than 100 different types of HPVs have been fully characterized . Warts may exist in different forms according to the epithelial surface affected and HPV type responsible for the infection. Common warts (Verruca vulgaris), plantar warts (Verruca plantaris), flat or plane warts (Verruca plana) and genital warts (Condyloma acuminata) are some of the clinical manifestations of HPV infection .
Although lesions can resolve spontaneously within 2 years without treatment, treatment is sought by many who are unwilling to wait for spontaneous clearance, by those who do not experience such resolution and for reasons of preventing infections of other individuals and reducing the risk of malignancy . Additionally, pain, discomfort, recurrent bleeding, functional limitation, and esthetic disfigurements due to cutaneous warts are common indications for seeking treatment.
Several therapeutic modalities have been used to treat HPV infections. The choice of treatment should take into account factors such as age, location, number and size of the lesions, clinical subtype and the patient's immunological status.
Available treatments are aimed at either breakdown or removal of visible warts or induction of cytotoxicity against infected cells .
They include destructive agents (keratolytic, cryotherapy, curettage and cautery, laser, photodynamic therapy), antimitotic agents (podophyllin, bleomycin, retinoids), immune stimulants (topical sensitizers, cimetidine), and topical virucidal agents [formaldehyde (formalin), glutaraldehyde (Glutaral) .
Unfortunately, no single treatment is satisfactory for all patients. Many treatments are time consuming, painful and can leave scars or hypopigmentation; moreover, recurrence rates after any treatment range from 6% to 100% . So, the development of new effective and safe treatments seems to be an urgent need.
Cryocautery represents a first line of therapy for cutaneous warts. It uses liquid nitrogen to freeze tissues and destroy warts.
Liquid nitrogen cryotherapy involves freezing a wart with liquid nitrogen for 10 to 20 seconds every two to three weeks. Precisely how cryotherapy destroys warts is not well understood, but the prevailing theory is that freezing causes local irritation, leading the host to mount an immune reaction against the virus.
However, side effects for cryocautery are common, they include pain, depigmentation, delayed healing, ulceration, scar formation and recurrence
Platelet- rich plasma (PRP) is a small volume of plasma rich in platelets. It has become a hopeful therapy in the last decade to treat several cutaneous diseases due to its increased concentrations of growth factors. As it is of autologous origin, it reduces the possibility of adverse effects and transfusion transmitted infections.
PRP has been utilized in the treatment of numerous cutaneous diseases such as alopecia, skin ulcers, and acne vulgaris. Its utility has been extended to other cutaneous diseases as melasma, hyperpigmentation, and burns, in addition to its usefulness in tissue repair and regeneration.
To the best of our knowledge the efficacy of PRP in the treatment of plane warts was assessed in a single uncontrolled clinical trial which revealed that intralesional injection of PRP was effective and well-tolerated immunotherapy for treating of multiple recalcitrant plane warts.
Moreover, complete remission of multiple resistant plantar warts after treatment by combined intralesional autologous PRP injections and local application of salicylic acid 30% was observed in only one case report.
Mechanisms suggested for such promising response of warts to intralesional injection of PRP included induction of expression of numerous pro-inflammatory cytokines as interleukin-6, interleukin-8, tumor necrosis factor-alpha, and C-C motif chemokine ligand 5 which then activate several immune cells leading to increased inflammation.
Also, platelets expressed CD40L, on its activation; it modulates its interaction with CD40 presenting on macrophages, B-cells, monocytes, endothelial cells, dendritic cells, and mediates their activities.
Platelets may modulate the innate immunity and provide antimicrobial activities either by synthesis of antimicrobial peptides or by modulating the immune activities of other immune cells as neutrophils and monocytes.
These interesting findings open the way for future studies to evaluate the usefulness of PRP in treating different clinical types of warts.
Metformin, a widely used drug to treat type 2 diabetes mellitus and metabolic syndrome, has been used systemically in different dermatological diseases such as hormonal acne, hidradenitis suppurativa (HS) and acanthosis nigricans in which it may act through improving hyperinsulinemia . Additionally, it was found effective when used topically in treatment of melasma with an equivalent effect to triple combination cream , and acne vulgaris .
Metformin has immunomodulatory activity that reduces the production of proinflammatory cytokines, it also inhibits the cytokine production of pathogenic Th1 and Th17 cells .
Furthermore, many studies, both in vitro and in vivo with small animal models, have highlighted the antiviral properties of metformin.
Additionally, Metformin has shown antitumorigenic potential in HPV-positive cancer cells. Such properties suggests that metformin might be effective therapeutic option for viral warts. However, to the best of our knowledge, no studies have been conducted to explore that hypothesis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Intralesional injection of Metformin | Experimental | Drug: MetforminGroup 1: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of metformin using insulin syringe every 2-weeks until complete clearance or for a maximum of 6 sessions. |
| Intralesional injection of platelet- rich plasma | Experimental | Drug: platelet-rich plasmaGroup 2: will include 36 patients with multiple common, plantar and/or plane warts. They will be treated by intralesional injection of platelet- rich plasma into the warts by an insulin syringe every 2 weeks until complete clearance or for a maximum of 6 sessions |
| Cryotherapy | Experimental | Other: cryotherapyGroup 3: will include 36 patients with multiple common, plantar and/or plane warts. They will receive cryotherapy sessions every two weeks until complete clearance or for a maximum of 6 sessions. |
Who may qualify
- Ages
- 8 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Patients with cutaneous (extragenital) viral warts (single , new or recurrent, common, plane and/or planter warts.
- Age ranged from 8 to 60 years old.
- No concurrent systemic or topical treatment of warts.
Key exclusion criteria (7 listed)
- Patients with fever or signs of any inflammation or infection
- Pregnancy and lactation.
- Immunosuppression or being under any kind of treatment causing absolute or relative immunosuppression.
- History of any bleeding, clotting disorder or using anticoagulants
- Chronic systemic diseases such as diabetes, chronic renal failure, hepatic insufficiency, and cardiovascular disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| platelet-rich plasmaplatelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts | Drug | Intralesional injection of platelet- rich plasma |
| Metforminplatelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts | Drug | Intralesional injection of Metformin |
| cryotherapyplatelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts | Other | Cryotherapy |
Primary outcome
Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings
Time frame: 3 months
Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings
3 secondary outcomes
•Change in size in millemeter
Time frame: 3 months
•Decrease in numbers of the warts
Time frame: 3 months
•Recurrence rates at 3 months for wart(s) with complete resolution.
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2024.
- Background: PubMed 36117295Zhu P, Qi RQ, Yang Y, Huo W, Zhang Y, He L, Wang G, Xu J, Zhang F, Yang R, Tu P, Ma L, Liu Q, Li Y, Gu H, Cheng B, Chen X, Chen A, Xiao S, Jin H, Zhang J, Li S, Yao Z, Pan W, Yang H, Shen Z, Cheng H, Song P, Fu L, Chen H, Geng S, Zeng K, Wang J, Tao J, Chen Y, Wang X, Gao XH. Clinical guideline for the diagnosis and treatment of cutaneous warts (2022). J Evid Based Med. 2022 Sep;15(3):284-301. doi: 10.1111/jebm.12494. Epub 2022 Sep 18.
- Background: PubMed 33637397Araujo MG, Magalhaes GM, Garcia LC, Vieira EC, Carvalho-Leite MLR, Guedes ACM. Update on human papillomavirus - Part II: complementary diagnosis, treatment and prophylaxis. An Bras Dermatol. 2021 Mar-Apr;96(2):125-138. doi: 10.1016/j.abd.2020.11.005. Epub 2021 Feb 16.
- Background: PubMed 25273231Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol. 2014 Oct;171(4):696-712. doi: 10.1111/bjd.13310. Epub 2014 Oct 1. No abstract available.
- Background: PubMed 16127954Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician. 2005 Aug 15;72(4):647-52.
- Background: PubMed 12361440Focht DR 3rd, Spicer C, Fairchok MP. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch Pediatr Adolesc Med. 2002 Oct;156(10):971-4. doi: 10.1001/archpedi.156.10.971.
- Background: PubMed 33599062Abu El-Hamd M, Aboeldahab S. Possible clinical efficacy and tolerability of platelet-rich plasma in the treatment of patients with recalcitrant plane warts: The first clinical study. J Cosmet Dermatol. 2021 Nov;20(11):3623-3629. doi: 10.1111/jocd.14008. Epub 2021 Mar 1.
- Background: PubMed 34559938Abu El-Hamd M, Aboeldahab S. A case of resistant multiple plantar warts cured with combined autologous platelet-rich plasma injection and topical salicylic acid 30. J Cosmet Dermatol. 2022 Jun;21(6):2417-2419. doi: 10.1111/jocd.14468. Epub 2021 Sep 24.
- Background: PubMed 31681291McDonald B, Dunbar M. Platelets and Intravascular Immunity: Guardians of the Vascular Space During Bloodstream Infections and Sepsis. Front Immunol. 2019 Oct 11;10:2400. doi: 10.3389/fimmu.2019.02400. eCollection 2019.
- Background: PubMed 9468137Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 Feb 5;391(6667):591-4. doi: 10.1038/35393.
- Background: PubMed 20213276Flad HD, Brandt E. Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci. 2010 Jul;67(14):2363-86. doi: 10.1007/s00018-010-0306-x. Epub 2010 Mar 7.
- Background: PubMed 32973814Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury. Front Immunol. 2020 Aug 18;11:2056. doi: 10.3389/fimmu.2020.02056. eCollection 2020.
- Background: PubMed 33348714Benedetti F, Sorrenti V, Buriani A, Fortinguerra S, Scapagnini G, Zella D. Resveratrol, Rapamycin and Metformin as Modulators of Antiviral Pathways. Viruses. 2020 Dec 17;12(12):1458. doi: 10.3390/v12121458.
Related trials for Non-Genital Warts
Not yet recruitingEarly Phase 1
the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.
Warts
Active, not recruitingPhase 3
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
Cervical Cancer, Condylomata Acuminata
Not yet recruitingPhase 2
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
HPV Infection, Cervical Cancer
RecruitingObservational study
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
HPV Infections, Cervical Cancer Stage IIa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eman Mohamed Kamal Elsayed Youssef, prof principal investigator
Professor of Dermatology and Venereology Faculty of Medicine, Assiut University
Alaa Mohamed Mahmoud Hamdy Ghazally, Lecturer principal investigator
Lecturer of Dermatology and Venereology Faculty of Medicine, Assiut University
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing platelet-rich plasma, Metformin and cryotherapy in people with Non-Genital Warts, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aya Gamal Abd El-Wahab Mahmoud (01151448835, geemy2011@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06691542, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.